IDO, PTEN-expressing Tregs and control of antigen-presentation in the murine tumor microenvironment

No abstract is available for this paper.

• Publication year

  2017

• Venue

  Cancer Immunology and Immunotherapy

• Publication date

  2017-05-09

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1007/s00262-017-2010-2PMID 28488123PMCID PMC5627605
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• AKT isoforms modulate Th1‐like Treg generation and function in human autoimmune disease

  2019cited by this paper
• First-in-Human Phase I Study of the Oral Inhibitor of Indoleamine 2,3-Dioxygenase-1 Epacadostat (INCB024360) in Patients with Advanced Solid Malignancies

  2017cited by this paper
• Evaluation of Immune-Related Response Criteria and RECIST v1.1 in Patients With Advanced Melanoma Treated With Pembrolizumab.

  2016cited by this paper
• Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.

  2016cited by this paper
• Neoantigen landscape dynamics during human melanoma–T cell interactions

  2016cited by this paper
• A phase I study of indoximod in patients with advanced malignancies

  2016cited by this paper
• AKT isoforms modulate Th1‐like Treg generation and function in human autoimmune disease

  2016cited by this paper
• Phase 2 trial of the indoleamine 2,3-dioxygenase pathway (IDO) inhibitor indoximod plus gemcitabine/nab-paclitaxel for the treatment of metastatic pancreas cancer: Interim analysis.

  2016cited by this paper
• ACTR-53. INTERIM ANALYSIS OF PHASE 1B/2 COMBINATION STUDY OF THE IDO PATHWAY INHIBITOR INDOXIMOD WITH TEMOZOLOMIDE FOR ADULT PATIENTS WITH TEMOZOLOMIDE-REFRACTORY PRIMARY MALIGNANT BRAIN TUMORS

  2016cited by this paper
• IDO in the Tumor Microenvironment: Inflammation, Counter-Regulation, and Tolerance.

  2016cited by this paper
• MicroRNA-17 Modulates Regulatory T Cell Function by Targeting Co-regulators of the Foxp3 Transcription Factor.

  2016cited by this paper
• Stress Kinase GCN2 Controls the Proliferative Fitness and Trafficking of Cytotoxic T Cells Independent of Environmental Amino Acid Sensing.

  2016cited by this paper
• Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade

  2016cited by this paper
• The amino acid sensor GCN2 controls gut inflammation by inhibiting inflammasome activation

  2016cited by this paper
• Tumor-specific cytotoxic T lymphocyte activity determines colorectal cancer patient prognosis.

  2015cited by this paper
• Combinatorial Strategies for the Induction of Immunogenic Cell Death

  2015cited by this paper
• Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents.

  2015cited by this paper
• Is all cancer therapy immunotherapy?

  2015cited by this paper
• The chromatin-modifying enzyme Ezh2 is critical for the maintenance of regulatory T cell identity after activation.

  2015cited by this paper
• GCN2 sustains mTORC1 suppression upon amino acid deprivation by inducing Sestrin2

  2015cited by this paper
• Regulatory T Cells in Tumor-Associated Tertiary Lymphoid Structures Suppress Anti-tumor T Cell Responses.

  2015cited by this paper
• Regulatory T cells require the phosphatase PTEN to restrain type 1 and follicular helper T-cell responses

  2015cited by this paper
• Stable inhibitory activity of regulatory T cells requires the transcription factor Helios

  2015cited by this paper
• PTEN inhibitors: an evaluation of current compounds.

  2015cited by this paper
• The energy sensor AMPK regulates T cell metabolic adaptation and effector responses in vivo.

  2015cited by this paper
• The amino acid sensor GCN2 inhibits inflammatory responses to apoptotic cells promoting tolerance and suppressing systemic autoimmunity

  2015cited by this paper
• Immune response to cancer therapy: mounting an effective antitumor response and mechanisms of resistance.

  2015cited by this paper
• The PTEN pathway in Tregs is a critical driver of the suppressive tumor microenvironment

  2015cited by this paper
• Combinatorial Strategies for the Induction of Immunogenic Cell Death

  2015cited by this paper
• The phosphatase PTEN-mediated control of PI-3 kinase in Tregs cells maintains homeostasis and lineage stability

  2014cited by this paper
• PD-1 blockade induces responses by inhibiting adaptive immune resistance

  2014cited by this paper
• Dynamic Treg interactions with intratumoral APCs promote local CTL dysfunction.

  2014cited by this paper
• Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients

  2014cited by this paper
• Inactivation of the PI3K p110δ breaks regulatory T cell-mediated immune tolerance to cancer

  2014cited by this paper
• Improved Survival with T Cell Clonotype Stability After Anti–CTLA-4 Treatment in Cancer Patients

  2014cited by this paper
• Continuous requirement for the T cell receptor for regulatory T cell function

  2014cited by this paper
• Anti–CTLA-4 therapy broadens the melanoma-reactive CD8+ T cell response

  2014cited by this paper
• Durable Therapeutic Efficacy Utilizing Combinatorial Blockade against IDO, CTLA-4, and PD-L1 in Mice with Brain Tumors

  2014cited by this paper
• Regulatory T cells in cancer immunotherapy.

  2014cited by this paper
• The indoleamine 2,3-dioxygenase pathway controls complement-dependent enhancement of chemo-radiation therapy against murine glioblastoma

  2014cited by this paper
• Marginal zone CD169+ macrophages coordinate apoptotic cell-driven cellular recruitment and tolerance

  2014cited by this paper
• Amino acid signalling upstream of mTOR

  2013cited by this paper
• An inherently bifunctional subset of Foxp3+ T helper cells is controlled by the transcription factor eos.

  2013cited by this paper
• Stability and function of regulatory T cells is maintained by a neuropilin-1–semaphorin-4a axis

  2013cited by this paper
• Indoleamine 2,3 dioxygenase and metabolic control of immune responses.

  2013cited by this paper
• Self-antigen-driven activation induces instability of regulatory T cells during an inflammatory autoimmune response.

  2013cited by this paper
• Oncology meets immunology: the cancer-immunity cycle.

  2013cited by this paper
• Control of inflammation by integration of environmental cues by regulatory T cells.

  2013cited by this paper
• FOXO transcription factors throughout T cell biology

  2012cited by this paper
• Engineering DNA Nanoparticles as Immunomodulatory Reagents that Activate Regulatory T Cells

  2012cited by this paper
• Surgical Stress Resistance Induced by Single Amino Acid Deprivation Requires Gcn2 in Mice

  2012cited by this paper
• Autoimmunity, intestinal lymphoid hyperplasia, and defects in mucosal B-cell homeostasis in patients with PTEN hamartoma tumor syndrome.

  2012cited by this paper
• Tolerance to apoptotic cells is regulated by indoleamine 2,3-dioxygenase

  2012cited by this paper
• Physiologic Control of IDO Competence in Splenic Dendritic Cells

  2011cited by this paper
• Pro-senescence therapy for cancer treatment

  2011cited by this paper
• Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice.

  2010cited by this paper
• Characterisation of the PTEN inhibitor VO-OHpic

  2010cited by this paper
• Foxo transcription factors control regulatory T cell development and function.

  2010cited by this paper
• Reprogrammed foxp3(+) regulatory T cells provide essential help to support cross-presentation and CD8(+) T cell priming in naive mice.

  2010cited by this paper
• Indoleamine 2,3-dioxygenase controls conversion of Foxp3+ Tregs to TH17-like cells in tumor-draining lymph nodes.

  2009cited by this paper
• PD-L1 regulates the development, maintenance, and function of induced regulatory T cells

  2009cited by this paper
• IDO Activates Regulatory T Cells and Blocks Their Conversion into Th17-Like T Cells1

  2009cited by this paper
• Instability of the transcription factor Foxp3 leads to the generation of pathogenic memory T cells in vivo

  2009cited by this paper
• Nuclear expression of the non B-cell lineage Sox11 transcription factor identifies mantle cell lymphoma.

  2008cited by this paper
• Plasmacytoid dendritic cells from mouse tumor-draining lymph nodes directly activate mature Tregs via indoleamine 2,3-dioxygenase.

  2007cited by this paper
• Inhibition of indoleamine 2,3-dioxygenase in dendritic cells by stereoisomers of 1-methyl-tryptophan correlates with antitumor responses.

  2007cited by this paper
• The Combined Effects of Tryptophan Starvation and Tryptophan Catabolites Down-Regulate T Cell Receptor ζ-Chain and Induce a Regulatory Phenotype in Naive T Cells1

  2006influential reference
• Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy

  2005cited by this paper
• GCN2 kinase in T cells mediates proliferative arrest and anergy induction in response to indoleamine 2,3-dioxygenase.

  2005cited by this paper
• Activation requirements for the induction of CD4+CD25+ T cell suppressor function

  2004cited by this paper
• T cell-specific loss of Pten leads to defects in central and peripheral tolerance.

  2001cited by this paper
• Impaired Fas response and autoimmunity in Pten+/- mice.

  1999cited by this paper

• Metabolomic and transcriptomic analyses identify metabolic alterations and immune suppression in ovarian cancer

  2026cites this paper
• mRNA-delivery of IDO1 suppresses T cell-mediated autoimmunity

  2024cites this paper
• Molecular mechanisms and therapeutic significance of Tryptophan Metabolism and signaling in cancer

  2024cites this paper
• Immunomodulatory Effects of MDA-MB-231-derived Exosome Mimetic Nanovesicles on CD4+ T Cell Line

  2024cites this paper
• IDO-1 impairs antitumor immunity of natural killer cells in triple-negative breast cancer via up-regulation of HLA-G

  2023cites this paper
• Classification of regulatory T cells and their role in myocardial ischemia-reperfusion injury.

  2023cites this paper
• A Study on Curcumol Influencing Proliferation and Apoptosis of Hepatocellular Carcinoma Cells through DJ-1/PTEN/PI3K/AKT Pathway

  2022cites this paper
• Metabolic reprogramming drives homeostasis and specialization of regulatory T cells in cancer

  2022cites this paper
• PTEN gene and AKT/mTOR pathway in gynecological cancers and cancer immune escape

  2022cites this paper
• Functional Diversities of Regulatory T Cells in the Context of Cancer Immunotherapy

  2022cites this paper
• The complex roles of efferocytosis in cancer development, metastasis, and treatment.

  2021cites this paper
• Metabolic Stress and Immunity: Nutrient-Sensing Kinases and Tryptophan Metabolism.

  2021cites this paper
• Emerging Roles on Immunological Effect of Indoleamine 2,3-Dioxygenase in Liver Injuries

  2021cites this paper
• Peptide vaccine-conjugated mesoporous carriers synergize with immunogenic cell death and PD-L1 blockade for amplified immunotherapy of metastatic spinal

  2021cites this paper
• Nanoparticle-mediated synergistic chemoimmunotherapy for tailoring cancer therapy: recent advances and perspectives

  2021cites this paper
• PTEN Function at the Interface between Cancer and Tumor Microenvironment: Implications for Response to Immunotherapy

  2020cites this paper
• FoxP3, CTLA-4, and IDO in Canine Melanocytic Tumors

  2020cites this paper
• Strategies to Target Tumor Immunosuppression

  2020cites this paper
• Immunostimulatory biomaterials to boost tumor immunogenicity.

  2020cites this paper
• Revising PTEN in the Era of Immunotherapy: New Perspectives for an Old Story

  2019cites this paper
• IDO and intra‐tumoral neutrophils were independent prognostic factors for overall survival for hepatocellular carcinoma

  2019cites this paper
• IDO1 Inhibition Overcomes Radiation-Induced "Rebound Immune Suppression" by Reducing Numbers of IDO1-Expressing Myeloid-Derived Suppressor Cells in the Tumor Microenvironment.

  2019cites this paper
• AutologousDendritic Cell-Cytokine InducedKiller Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer : A Prospective Study

  2019cites this paper
• Cancer nanomedicine for combination cancer immunotherapy

  2019cites this paper
• Sexual Dimorphism of Immune Responses: A New Perspective in Cancer Immunotherapy

  2018influential citation
• 1-LMT , an IDO inhibitor , prevented colitis-associated cancer by inducing CDC 20 inhibition-mediated mitotic death of colon cancer cells

  2018cites this paper
• Indoximod: An Immunometabolic Adjuvant That Empowers T Cell Activity in Cancer

  2018cites this paper
• Targeting the IDO1 pathway in cancer: from bench to bedside

  2018cites this paper
• 1‐L‐MT, an IDO inhibitor, prevented colitis‐associated cancer by inducing CDC20 inhibition‐mediated mitotic death of colon cancer cells

  2018cites this paper
• FOXP3+ Treg as a therapeutic target for promoting anti-tumor immunity

  2018cites this paper
• Effects of PHA-665752 and vemurafenib combination treatment on in vitro and murine xenograft growth of human colorectal cancer cells with BRAFV600E mutations.

  2018cites this paper
• Autologous Dendritic Cell-Cytokine Induced Killer Cell Immunotherapy Combined with S-1 Plus Cisplatin in Patients with Advanced Gastric Cancer: A Prospective Study

  2018cites this paper
• PTEN expression by an oncolytic herpesvirus directs T-cell mediated tumor clearance

  2018cites this paper
• Combination Therapy with EpCAM-CAR-NK-92 Cells and Regorafenib against Human Colorectal Cancer Models

  2018cites this paper
• Encéphalites à anticorps anti-NMDAR : étude clinique et mécanistique

  2017cites this paper
• Inflammatory Reprogramming with IDO1 Inhibitors: Turning Immunologically Unresponsive 'Cold' Tumors 'Hot'.

  2017cites this paper
• Chimeric antigen receptor-T cell therapy for solid tumors require new clinical regimens

  2017cites this paper
• Synergistic Effects of Cabozantinib and EGFR-Specific CAR-NK-92 Cells in Renal Cell Carcinoma

  2017cites this paper
• an investigation on immunoescape pathways

  year unknowncites this paper